GALIMBERTI et al. V. ASANUMA et al. - Page 15




          Interference No. 103,303                                                    


          and lack of other examples in the Asanuma et al. application                
          showing copolymers having butene units less than 11.8 mole %                
          are not relevant to the consideration of the question of no                 
          interference-in-fact.  As we noted above, the test for no                   
          interference-in-fact is a showing that the party Galimberti et              
          al.'s claim 1 is patentably distinct from the party Asanuma et              
          al.'s claims 9                                                              
          and 11.                                                                     
               The party Galimberti et al. has not alleged any                        
          criticality in the range of 1.3 to 10 mole % for its 1-butene               
          monomer vis-à-vis the range of 1 to 24 mole % recited in the                
          party Asanuma et al.'s claim 11 for its butene monomer.  Nor                
          has the party Galimberti et al. alleged any criticality in its              
          copolymer having a fraction soluble in xylene less than 10% by              
          weight.  Rather, the party Galimberti et al. argues three                   
          differences between its claim 1 and claims 9 and 11 of the                  
          party Asanuma et al.  These differences are (1) the Galimberti              
          et al.'s copolymers are homogenous whereas the Asanuma                      
          copolymers are not, (2) the Galimberti et al. copolymers have               
          a fraction soluble in xylene less than 10% by weight whereas                
          the Asanuma copolymers do not, and (3) the Galimberti et al.                
          copolymers are made by a different process than the Asanuma                 
                                        -15-                                          




Page:  Previous  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  Next 

Last modified: November 3, 2007